CABA

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis2 trials
• Chronic spontaneous urticaria1 trial
• COPD1 trial
• Sjögren's disease1 trial

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Completed4 trials
• Active, not recruiting1 trial

Lead sponsor

• Sanofi5 trials

Running trials

• Active, not recruiting

  A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

  NCT06372145· Phase 3· Sanofi· Source

Closed trials

• Completed

  Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

  NCT04572841· Phase 2· Sanofi· Source

• Completed

  Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

  NCT04456673· Phase 3· Sanofi· Source

• Completed

  Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

  NCT04410991· Phase 3· Sanofi· Source

• Completed

  Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

  NCT04180488· Phase 3· Sanofi· Source